Skip to content
Sign in
Health · Asia

India approves Zytorvi with chemotherapy for advanced esophageal cancer

India’s drug regulator approved Dr. Reddy’s Laboratories’ Zytorvi with chemotherapy as a first-line treatment for adults with advanced esophageal squamous cell carcinoma. The approval adds a second Indian indication for the drug, and the treatment does not require selection by PD-L1 status.

AI-assisted synthesis · Based on 5 outlets' reporting · Article text read from 3 of 5 outletsHow it's made

View timeline · 5 entries
5 outletsLatest reporting 3 min read
Coverage: Center OnlyL 0 · C 3 · R 0 · 2 unrated
Updat3 graphic: India
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • India’s drug regulator approved Dr. Reddy’s Laboratories’ Zytorvi (toripalimab) for first-line treatment of adults with advanced esophageal squamous cell carcinoma (per businessupturn.com, business-standard.com, rediff.com).
  • The approved treatment combines Zytorvi with cisplatin and paclitaxel for adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (per businessupturn.com, business-standard.com).
  • Zytorvi’s approval for esophageal squamous cell carcinoma is its second indication in India, following its November 2024 launch for nasopharyngeal carcinoma (per businessupturn.com, business-standard.com, expresspharma.in).
  • Final overall-survival analysis in JUPITER-06 found median survival of 17.7 months with toripalimab and chemotherapy, compared with 12.9 months with chemotherapy alone (per businessupturn.com, business-standard.com).
  • JUPITER-06 reported a 42% lower risk of disease progression or death with toripalimab plus chemotherapy than with chemotherapy alone (per businessupturn.com).
  • The Indian indication does not require patient selection by PD-L1 expression, and the company reported clinical benefit across PD-L1 subgroups (per businessupturn.com).

The brief

India’s drug regulator has approved Dr. Reddy’s Laboratories’ Zytorvi, also known as toripalimab, with chemotherapy as a first-line treatment for adults with advanced esophageal squamous cell carcinoma. The approved regimen combines the drug with cisplatin and paclitaxel.

The indication covers unresectable advanced, recurrent or metastatic disease, and is the medicine’s second approved use in India. The approval letter is dated September 24, 2026; Dr. Reddy’s announced the clearance to stock exchanges on October 21. The company said the new indication does not require doctors to select patients according to PD-L1 expression, a tumor biomarker.

It reported clinical benefit across PD-L1 subgroups, allowing consideration of the treatment regardless of that biomarker status. The clearance rests on the Phase 3 JUPITER-06 trial. In its final overall-survival analysis, median survival was 17.7 months among patients receiving toripalimab with chemotherapy, compared with 12.9 months for those receiving chemotherapy alone.

The trial also reported a 42% reduction in the risk of disease progression or death with the combination relative to chemotherapy alone. These figures are clinical trial results reported by the company, not a guarantee of outcome for an individual patient. The new use follows Zytorvi’s earlier Indian approval for nasopharyngeal carcinoma. Dr.

Reddy’s launched the drug for that cancer in November 2024; the esophageal cancer authorization expands its approved uses in the country. The two indications concern different cancers, and the new clearance specifically addresses esophageal squamous cell carcinoma. Business Standard and Express Pharma report that Dr.

Reddy’s has a licensing and commercialisation agreement with Junshi Biosciences covering toripalimab in 21 countries. That commercial arrangement provides the context for the company’s role in developing and marketing the drug beyond India; the sources do not connect it to the regulator’s decision.

Business Standard and Express Pharma also cite company-reported estimates that esophageal cancer ranked fourth among causes of cancer-related death in India in 2024 and accounted for about 8.1% of such deaths. Express Pharma adds that the squamous cell subtype represents about 80% of esophageal cancer cases in India.

Those figures describe the disease burden and subtype, while the approval applies to the specific squamous cell cancer indication. The next concrete point for patients and clinicians is how the approved combination is considered in treatment decisions, including for patients with different PD-L1 expression levels.

The reported trial comparisons and the regulator’s broad biomarker eligibility are the central evidence and prescribing features of this new Indian indication.

Why it matters

  • Adults in India with advanced esophageal squamous cell carcinoma are the population directly affected: the approval makes a first-line combination of toripalimab, cisplatin and paclitaxel an authorized treatment option.
  • The trial’s reported median overall survival was 17.7 months with the combination and 12.9 months with chemotherapy alone, a 4.8-month difference between the reported medians.
  • Patients do not need to meet a PD-L1 expression threshold for the Indian indication, according to the approval description; the company reported clinical benefit across PD-L1 subgroups.
  • Dr. Reddy’s Laboratories and Junshi Biosciences have a licensing and commercialisation agreement covering 21 countries, establishing a documented commercial interest in toripalimab.

What to watch next

  • Whether clinicians consider the approved cisplatin-and-paclitaxel combination for eligible adults across PD-L1 expression groups.
  • How Dr. Reddy’s Laboratories implements the new Indian indication following its October 21, 2026 announcement.
  • How the company positions Zytorvi’s esophageal cancer use alongside its existing Indian indication for nasopharyngeal carcinoma.
  • Whether additional details about the JUPITER-06 results or the approved treatment are reported by Dr. Reddy’s Laboratories.

How it's being covered

Coverage analysisShow details
5 source articles · 5 unique outlets
Outlet political mix: Center Only· 3 Center · 2 unrated
Where the outlets are based: Asia 80% · Unknown 20%
Outlet political mix
Center Only
Left
Center
Right
0 outlets
3 outlets
0 outlets
The marker shows coverage balance: each unique outlet counts once. 2 unrated outlets are not included.
Geography
Where the outlets covering this story are based.
5 unique outletsDominant coverage: Asia
Coverage imbalance
  • Coverage is currently concentrated among Center-rated outlets (3 of 3 rated sources); comparatively few Left or Right-rated outlets have published on the event.
  • Coverage is currently concentrated among outlets based in Asia (4 of 5 geographically-identified sources).
How we measure coverage

How outlets' accounts compare

2 framing differences · 2 uncorroborated claims · 3 information gaps
The reports repeat the same account with different emphasis; its central claims are not independently confirmed in the reporting Updat3 read.Compared across 3 reports whose article text Updat3 read; 2 other outlets were checked by headline only.
Framing / emphasis differences
Sources emphasise different angles, actors or consequences of the same reporting.
  • BusinessUpturn gives more detail on the approved regimen, the approval letter date, the 42% progression-or-death risk reduction and the final survival analysis; Business Standard emphasizes the second Indian indication and the licensing arrangement.
  • Express Pharma adds national disease-burden estimates and the proportion of esophageal cancers that are squamous cell, while BusinessUpturn focuses on the approval and trial outcomes.
Updat3: These are differences of emphasis, not disputes about what is reported. They do not show that the reported claims are true.
One-sided or uncorroborated claims
Claims that come from one party or one source family and are not independently corroborated.
  • BusinessUpturn reports that the company said clinical benefit was seen across PD-L1 subgroups.
  • Business Standard and Express Pharma report that esophageal cancer accounted for approximately 8.1% of cancer-related deaths in India in 2024, citing company-reported estimates.
Updat3: Not independently corroborated yet — treat as a claim, not an established fact.
Not established by the reporting
Information the available reporting does not contain or confirm. This is a gap, not a disagreement.
  • The sources do not provide pricing, reimbursement, availability, or patient-level eligibility details beyond the indication and PD-L1 status.
  • The sources do not provide independent clinical or regulatory assessments of the trial results.
  • The sources do not provide independently verified trial data; the clinical results are reported as findings of JUPITER-06, with BusinessUpturn explicitly describing the data as reported by the company.
Updat3: Updat3 cannot conclude anything about this from the current sources.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. India enacted the Drugs and Cosmetics Act, establishing the statutory framework for regulating medicines.
    Background · compiled and fact-checked by Updat3
  2. China approved toripalimab for advanced melanoma.
    Background · compiled and fact-checked by Updat3
  3. India issued the New Drugs and Clinical Trials Rules, setting requirements for new-drug approvals and clinical trials.
    Background · compiled and fact-checked by Updat3
  4. The U.S. Food and Drug Administration approved toripalimab for nasopharyngeal carcinoma.
    Background · compiled and fact-checked by Updat3
  5. In November 2024, Dr. Reddy’s launched Zytorvi in India for nasopharyngeal carcinoma, its first Indian indication for toripalimab.
    Background · from our historical context

How we got here

In November 2024, Dr. Reddy’s launched Zytorvi in India for nasopharyngeal carcinoma, its first Indian indication for toripalimab. That launch followed the drug’s development and approvals abroad: China’s National Medical Products Administration approved toripalimab for advanced melanoma in 2018, and the U.S.

Food and Drug Administration approved it for nasopharyngeal carcinoma in 2023. The clinical evidence for using toripalimab against esophageal squamous cell carcinoma came from JUPITER-06, a phase 3 trial in China.

Original sources

1 of 5 articles · Unknown · Show all

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.